Dr. Robin Y. Dulman
Claim this profileInova Fairfax Hospital
Studies Leukemia
Studies Lymphoma
25 reported clinical trials
64 drugs studied
About Robin Y. Dulman
Education:
- Obtained MD from the University of Virginia School of Medicine in 2009.
- Completed Residency in Internal Medicine at the University of California, San Francisco (2009-2012).
- Undertook Fellowship in Pulmonary and Critical Care Medicine at the University of California, San Francisco (2012-2015).
Experience:
- Currently affiliated with Inova Fairfax Hospital as an Assistant Professor of Medicine.
- Specializes in Pulmonary and Critical Care Medicine.
Area of expertise
1Leukemia
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
2Lymphoma
Stage IV
Stage III
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Robin Y. Dulman is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting1 award Phase 212 criteria
More about Robin Y. Dulman
Clinical Trial Related4 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Robin Y. Dulman has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Doxorubicin Hydrochloride
- Radiation Therapy
- Nivolumab
Breakdown of trials Robin Y. Dulman has run
Leukemia
Lymphoma
Tumors
Lymphoblastic Leukemia-Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robin Y. Dulman specialize in?
Robin Y. Dulman focuses on Leukemia and Lymphoma. In particular, much of their work with Leukemia has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 fusion positive.
Is Robin Y. Dulman currently recruiting for clinical trials?
Yes, Robin Y. Dulman is currently recruiting for 8 clinical trials in Falls Church Virginia. If you're interested in participating, you should apply.
Are there any treatments that Robin Y. Dulman has studied deeply?
Yes, Robin Y. Dulman has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Robin Y. Dulman?
Apply for one of the trials that Robin Y. Dulman is conducting.
What is the office address of Robin Y. Dulman?
The office of Robin Y. Dulman is located at: Inova Fairfax Hospital, Falls Church, Virginia 22042 United States. This is the address for their practice at the Inova Fairfax Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.